JP2007533298A - Il−21の誘導体 - Google Patents

Il−21の誘導体 Download PDF

Info

Publication number
JP2007533298A
JP2007533298A JP2006529654A JP2006529654A JP2007533298A JP 2007533298 A JP2007533298 A JP 2007533298A JP 2006529654 A JP2006529654 A JP 2006529654A JP 2006529654 A JP2006529654 A JP 2006529654A JP 2007533298 A JP2007533298 A JP 2007533298A
Authority
JP
Japan
Prior art keywords
kda
derivative
peg
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006529654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533298A5 (cg-RX-API-DMAC7.html
Inventor
ペシュケ、ベルント
ショット、クリスチーヌ、ブルーン
ベルディケ、ヘレ
デルバルト、フロレンシオ、ザラゴザ
ボルサーエ、アンネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2007533298A publication Critical patent/JP2007533298A/ja
Publication of JP2007533298A5 publication Critical patent/JP2007533298A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2006529654A 2003-10-10 2004-10-08 Il−21の誘導体 Withdrawn JP2007533298A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200301496 2003-10-10
US51089203P 2003-10-14 2003-10-14
DKPA200301529 2003-10-17
US51342203P 2003-10-22 2003-10-22
DKPA200400707 2004-05-04
US56956604P 2004-05-10 2004-05-10
PCT/DK2004/000686 WO2005035565A1 (en) 2003-10-10 2004-10-08 Il-21 derivatives

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011087574A Division JP2011184442A (ja) 2003-10-10 2011-04-11 Il−21の誘導体
JP2011198348A Division JP2012067100A (ja) 2003-10-10 2011-09-12 Il−21の誘導体

Publications (2)

Publication Number Publication Date
JP2007533298A true JP2007533298A (ja) 2007-11-22
JP2007533298A5 JP2007533298A5 (cg-RX-API-DMAC7.html) 2010-10-07

Family

ID=42779898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006529654A Withdrawn JP2007533298A (ja) 2003-10-10 2004-10-08 Il−21の誘導体

Country Status (7)

Country Link
EP (2) EP2263684A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007533298A (cg-RX-API-DMAC7.html)
CN (2) CN1867581B (cg-RX-API-DMAC7.html)
AT (1) ATE481420T1 (cg-RX-API-DMAC7.html)
CA (1) CA2542179A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004029173D1 (cg-RX-API-DMAC7.html)
WO (1) WO2005035565A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2033662B1 (en) * 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
AU2006256802A1 (en) * 2005-06-06 2006-12-14 Novo Nordisk A/S Stabilised IL-21 compositions
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
WO2007071768A1 (en) 2005-12-23 2007-06-28 Novo Nordisk A/S Purification of proteins using preparative reverse phase chromatography (rpc)
WO2008003750A2 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
EP2109620B1 (en) 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
WO2015000585A1 (en) * 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
CN105198999A (zh) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 一种融合蛋白、其制备方法及其应用
SG11202107395VA (en) * 2019-01-21 2021-08-30 Sanofi Sa Therapeutic rna for advanced stage solid tumor cancers
WO2024002170A1 (en) * 2022-06-29 2024-01-04 Beijing Neox Biotech Limited Il-21 polypeptides and methods of use
CN117645661A (zh) * 2022-09-02 2024-03-05 北京志道生物科技有限公司 一种聚乙二醇修饰的il-21衍生物及其应用
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007938A1 (en) * 1989-01-23 1990-07-26 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー, インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体
JP2002516103A (ja) * 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド インターロイキン21およびインターロイキン22
JP2002537839A (ja) * 1999-03-09 2002-11-12 ザイモジェネティクス,インコーポレイティド 新規サイトカインzalpha11リガンド
WO2003006501A2 (en) * 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
WO2003028630A2 (en) * 2001-10-04 2003-04-10 Genetics Institute Llc. Methods and compositions for modulating interleukin-21 receptor activity
WO2003040313A2 (en) * 2001-11-05 2003-05-15 Zymogenetics, Inc Il-21 antagonists
WO2003103589A2 (en) * 2002-06-07 2003-12-18 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications
WO2004055168A2 (en) * 2002-12-13 2004-07-01 Zymogenetics, Inc. Il-21 production in prokaryotic hosts
JP2007501812A (ja) * 2003-08-08 2007-02-01 ノボ ノルディスク アクティーゼルスカブ ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
ES2092468T3 (es) 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ATE300519T1 (de) 1989-04-19 2005-08-15 Enzon Inc Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
CA2073511A1 (en) 1990-11-14 1992-05-29 Matthew R. Callstrom Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU1676992A (en) 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
CA2137087A1 (en) * 1992-06-01 1993-12-09 U. Prasad Kari Biologically active peptides having n-terminal substitutions
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
WO1995033490A1 (en) 1994-06-02 1995-12-14 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1996040248A1 (en) * 1995-06-07 1996-12-19 Eukarion, Inc. Transvacular and intracellular delivery of lipidized proteins
AU5893696A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP1731174A3 (en) 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
ATE469166T1 (de) 1997-06-06 2010-06-15 Kyowa Hakko Kirin Co Ltd Chemisch modifizierte polypeptide
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
PT1075282E (pt) 1998-04-28 2005-09-30 Applied Research Systems Conjugados analogos de peg-lhrh
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
AU2003230834A1 (en) 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
MXPA05000655A (es) 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007938A1 (en) * 1989-01-23 1990-07-26 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー, インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体
JP2002516103A (ja) * 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド インターロイキン21およびインターロイキン22
JP2002537839A (ja) * 1999-03-09 2002-11-12 ザイモジェネティクス,インコーポレイティド 新規サイトカインzalpha11リガンド
WO2003006501A2 (en) * 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
WO2003028630A2 (en) * 2001-10-04 2003-04-10 Genetics Institute Llc. Methods and compositions for modulating interleukin-21 receptor activity
WO2003040313A2 (en) * 2001-11-05 2003-05-15 Zymogenetics, Inc Il-21 antagonists
WO2003103589A2 (en) * 2002-06-07 2003-12-18 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications
JP2006514601A (ja) * 2002-06-07 2006-05-11 ザイモジェネティクス インコーポレイティッド ガンおよびその他の治療用途におけるil−21の使用方法
WO2004055168A2 (en) * 2002-12-13 2004-07-01 Zymogenetics, Inc. Il-21 production in prokaryotic hosts
JP2007501812A (ja) * 2003-08-08 2007-02-01 ノボ ノルディスク アクティーゼルスカブ ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用

Also Published As

Publication number Publication date
EP1673387A1 (en) 2006-06-28
CN102516386A (zh) 2012-06-27
CN1867581B (zh) 2012-02-01
DE602004029173D1 (de) 2010-10-28
ATE481420T1 (de) 2010-10-15
CA2542179A1 (en) 2005-04-21
CN1867581A (zh) 2006-11-22
EP1673387B1 (en) 2010-09-15
WO2005035565A1 (en) 2005-04-21
EP2263684A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
JP2011184442A (ja) Il−21の誘導体
JP7819087B2 (ja) インターロイキン-23受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
ES2349743T3 (es) Derivados de la il-21.
TWI882061B (zh) 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
US20250041431A1 (en) Controlled-release cnp agonists with increased nep stability
TWI792596B (zh) 新穎脂肪酸及其於共軛至生物分子之用途
JP2025134806A (ja) インターロイキン23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
KR102627405B1 (ko) 조절 방출 pth 화합물을 위한 투여 용법
TW202116793A (zh) 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途
CN105934257B (zh) 用于含氮和羟基的药物的生物可逆引入基团
CN109789188B (zh) 具有低峰-谷比的pth化合物
CA3007982C (en) Controlled-release cnp agonists with low initial npr-b activity
CA3007979C (en) Cnp prodrugs with carrier attachment at the ring moiety
JP2017523959A (ja) ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用
TW201127397A (en) Growth hormones with prolonged in-vivo efficacy
EP1673387B1 (en) Il-21 derivatives
KR20220097921A (ko) 인터루킨-22의 치료 유도체
AU2006215566A1 (en) Insulinotropic agents conjugated with structurally well defined branched polymers
EP1986694B1 (en) Coupling of polypeptides at the c-terminus
US20170246311A1 (en) Peptides for binding alternatively activated macrophages
JP2008516621A (ja) 成長ホルモン結合体
TW201808346A (zh) 長效調酸素調配物及其產生與投與方法
JP2007501813A (ja) 新生血管形成と関連した症状を治療および診断するためのインターロイキン−20
MXPA06004059A (en) Il-21 derivatives
TW202615456A (zh) 用於肥胖症及第二型糖尿病(t2dm)的雙重及三重促效劑化合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100720

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100727

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110309

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110912

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110926

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111024